|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TRIM21 |
Gene summary for TRIM21 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TRIM21 | Gene ID | 6737 |
| Gene name | tripartite motif containing 21 | |
| Gene Alias | RNF81 | |
| Cytomap | 11p15.4 | |
| Gene Type | protein-coding | GO ID | GO:0000209 | UniProtAcc | P19474 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6737 | TRIM21 | LZE4T | Human | Esophagus | ESCC | 8.33e-08 | 1.73e-01 | 0.0811 |
| 6737 | TRIM21 | LZE24T | Human | Esophagus | ESCC | 6.01e-10 | 3.31e-01 | 0.0596 |
| 6737 | TRIM21 | P2T-E | Human | Esophagus | ESCC | 9.36e-14 | 2.64e-01 | 0.1177 |
| 6737 | TRIM21 | P4T-E | Human | Esophagus | ESCC | 2.18e-03 | 9.24e-02 | 0.1323 |
| 6737 | TRIM21 | P8T-E | Human | Esophagus | ESCC | 4.31e-08 | 1.30e-01 | 0.0889 |
| 6737 | TRIM21 | P9T-E | Human | Esophagus | ESCC | 3.51e-11 | 2.84e-01 | 0.1131 |
| 6737 | TRIM21 | P11T-E | Human | Esophagus | ESCC | 2.37e-16 | 5.55e-01 | 0.1426 |
| 6737 | TRIM21 | P12T-E | Human | Esophagus | ESCC | 1.09e-03 | 1.15e-01 | 0.1122 |
| 6737 | TRIM21 | P15T-E | Human | Esophagus | ESCC | 1.21e-02 | 1.22e-01 | 0.1149 |
| 6737 | TRIM21 | P17T-E | Human | Esophagus | ESCC | 1.77e-11 | 4.53e-01 | 0.1278 |
| 6737 | TRIM21 | P20T-E | Human | Esophagus | ESCC | 2.13e-09 | 2.49e-01 | 0.1124 |
| 6737 | TRIM21 | P21T-E | Human | Esophagus | ESCC | 9.52e-07 | 1.48e-01 | 0.1617 |
| 6737 | TRIM21 | P22T-E | Human | Esophagus | ESCC | 5.67e-03 | 9.36e-02 | 0.1236 |
| 6737 | TRIM21 | P23T-E | Human | Esophagus | ESCC | 2.55e-08 | 2.33e-01 | 0.108 |
| 6737 | TRIM21 | P24T-E | Human | Esophagus | ESCC | 5.19e-09 | 2.34e-01 | 0.1287 |
| 6737 | TRIM21 | P26T-E | Human | Esophagus | ESCC | 4.38e-10 | 2.03e-01 | 0.1276 |
| 6737 | TRIM21 | P27T-E | Human | Esophagus | ESCC | 3.33e-06 | 8.05e-02 | 0.1055 |
| 6737 | TRIM21 | P28T-E | Human | Esophagus | ESCC | 9.48e-16 | 3.28e-01 | 0.1149 |
| 6737 | TRIM21 | P31T-E | Human | Esophagus | ESCC | 2.75e-14 | 2.27e-01 | 0.1251 |
| 6737 | TRIM21 | P32T-E | Human | Esophagus | ESCC | 6.62e-10 | 2.28e-01 | 0.1666 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0016032111 | Esophagus | ESCC | viral process | 301/8552 | 415/18723 | 3.34e-29 | 1.32e-26 | 301 |
| GO:0031647111 | Esophagus | ESCC | regulation of protein stability | 223/8552 | 298/18723 | 5.76e-25 | 1.52e-22 | 223 |
| GO:0009896111 | Esophagus | ESCC | positive regulation of catabolic process | 332/8552 | 492/18723 | 4.36e-23 | 9.22e-21 | 332 |
| GO:0031331111 | Esophagus | ESCC | positive regulation of cellular catabolic process | 292/8552 | 427/18723 | 8.67e-22 | 1.53e-19 | 292 |
| GO:0019058111 | Esophagus | ESCC | viral life cycle | 226/8552 | 317/18723 | 1.17e-20 | 1.76e-18 | 226 |
| GO:1903320111 | Esophagus | ESCC | regulation of protein modification by small protein conjugation or removal | 181/8552 | 242/18723 | 1.80e-20 | 2.60e-18 | 181 |
| GO:0051098111 | Esophagus | ESCC | regulation of binding | 251/8552 | 363/18723 | 6.73e-20 | 8.46e-18 | 251 |
| GO:001050617 | Esophagus | ESCC | regulation of autophagy | 220/8552 | 317/18723 | 6.72e-18 | 6.36e-16 | 220 |
| GO:000020917 | Esophagus | ESCC | protein polyubiquitination | 170/8552 | 236/18723 | 1.40e-16 | 1.09e-14 | 170 |
| GO:001908017 | Esophagus | ESCC | viral gene expression | 80/8552 | 94/18723 | 2.04e-15 | 1.28e-13 | 80 |
| GO:004312318 | Esophagus | ESCC | positive regulation of I-kappaB kinase/NF-kappaB signaling | 132/8552 | 186/18723 | 2.07e-12 | 8.58e-11 | 132 |
| GO:0050792111 | Esophagus | ESCC | regulation of viral process | 119/8552 | 164/18723 | 2.19e-12 | 9.03e-11 | 119 |
| GO:0043122110 | Esophagus | ESCC | regulation of I-kappaB kinase/NF-kappaB signaling | 167/8552 | 249/18723 | 6.11e-12 | 2.32e-10 | 167 |
| GO:0051099111 | Esophagus | ESCC | positive regulation of binding | 122/8552 | 173/18723 | 2.79e-11 | 9.45e-10 | 122 |
| GO:000724919 | Esophagus | ESCC | I-kappaB kinase/NF-kappaB signaling | 183/8552 | 281/18723 | 3.02e-11 | 1.01e-09 | 183 |
| GO:004339320 | Esophagus | ESCC | regulation of protein binding | 135/8552 | 196/18723 | 3.69e-11 | 1.22e-09 | 135 |
| GO:1903900111 | Esophagus | ESCC | regulation of viral life cycle | 106/8552 | 148/18723 | 1.26e-10 | 3.72e-09 | 106 |
| GO:0044403111 | Esophagus | ESCC | biological process involved in symbiotic interaction | 186/8552 | 290/18723 | 1.43e-10 | 4.16e-09 | 186 |
| GO:004578710 | Esophagus | ESCC | positive regulation of cell cycle | 196/8552 | 313/18723 | 9.27e-10 | 2.24e-08 | 196 |
| GO:0051701111 | Esophagus | ESCC | biological process involved in interaction with host | 135/8552 | 203/18723 | 1.49e-09 | 3.49e-08 | 135 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| TRIM21 | pDC | Lung | IAC | SPHK2,PDE7B,PADI2, etc. | 1.68e-02 |  |
| TRIM21 | NEUT | Lung | IAC | SPHK2,PDE7B,PADI2, etc. | 2.84e-02 | |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TRIM21 | SNV | Missense_Mutation | novel | c.1307N>C | p.Cys436Ser | p.C436S | P19474 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-A2-A4S1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TRIM21 | SNV | Missense_Mutation | rs768080889 | c.424N>A | p.Ala142Thr | p.A142T | P19474 | protein_coding | tolerated(0.16) | benign(0.417) | TCGA-B6-A0RG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TRIM21 | SNV | Missense_Mutation | rs376066276 | c.191N>A | p.Arg64Gln | p.R64Q | P19474 | protein_coding | tolerated(0.13) | probably_damaging(0.92) | TCGA-BH-A0AW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
| TRIM21 | SNV | Missense_Mutation | c.595G>A | p.Glu199Lys | p.E199K | P19474 | protein_coding | tolerated(1) | benign(0) | TCGA-BH-A0BM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| TRIM21 | SNV | Missense_Mutation | c.312G>T | p.Glu104Asp | p.E104D | P19474 | protein_coding | deleterious(0) | possibly_damaging(0.739) | TCGA-C8-A12Q-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| TRIM21 | insertion | Frame_Shift_Ins | novel | c.744_745insCTCTATTCCACTTGTGGGCTAGC | p.Ile249LeufsTer19 | p.I249Lfs*19 | P19474 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| TRIM21 | SNV | Missense_Mutation | c.388N>C | p.Glu130Gln | p.E130Q | P19474 | protein_coding | deleterious(0) | possibly_damaging(0.69) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
| TRIM21 | SNV | Missense_Mutation | novel | c.489N>C | p.Lys163Asn | p.K163N | P19474 | protein_coding | deleterious(0.02) | benign(0.022) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| TRIM21 | SNV | Missense_Mutation | c.175N>A | p.Leu59Met | p.L59M | P19474 | protein_coding | tolerated(0.22) | benign(0.173) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| TRIM21 | SNV | Missense_Mutation | rs764736589 | c.655G>T | p.Ala219Ser | p.A219S | P19474 | protein_coding | tolerated(0.3) | benign(0.02) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |